Assetmark Inc. raised its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) by 32.9% in the 4th quarter, ...

Ascendis Health's journey from near-bankruptcy to profitability showcases how strategic leadership and financial discipline ...

Ascendis also confirmed plans to submit regulatory filings for TransCon CNP as a treatment for children with achondroplasia. The board also authorized up to $18.25 million for repurchases of its ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a ...

Check Out Our Latest Analysis on Ascendis Pharma A/S Ascendis Pharma A/S Price Performance NASDAQ:ASND opened at $138.18 on Tuesday. The stock has a market cap of $8.39 billion, a P/E ratio of -19 ...

“Having achieved pivotal milestones in 2024, Ascendis is positioned to continue strong revenue growth in 2025 and beyond,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive ...

Buying $1000 In ASND: If an investor had bought $1000 of ASND stock 15 years ago, it would be worth $55,812.96 today based on a price of $151.93 for ASND at the time of writing.

Ascendis Pharma A/S (NASDAQ:ASND) defied analyst predictions to release its annual results, which were ahead of market expectations. The overall earnings picture was okay, with revenues of €364m ...

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual ...

On Wednesday, Ascendis Pharma (NASDAQ:ASND) reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros. Total revenue for the fourth quarter of 2024 was 173.9 million ...

Good day and thank you for standing by. Welcome to the Fourth Quarter and Full Year 2024 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.